BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7590650)

  • 1. Efficacy and safety of interferon alfa therapy in chronic hepatitis C with autoantibodies to liver-kidney microsomes.
    Todros L; Saracco G; Durazzo M; Abate ML; Touscoz G; Scaglione L; Verme G; Rizzetto M
    Hepatology; 1995 Nov; 22(5):1374-8. PubMed ID: 7590650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.
    Clifford BD; Donahue D; Smith L; Cable E; Luttig B; Manns M; Bonkovsky HL
    Hepatology; 1995 Mar; 21(3):613-9. PubMed ID: 7533120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of autoimmune and extra-hepatic manifestations of HCV infection.
    Lunel F; Cacoub P
    Ann Med Interne (Paris); 2000 Feb; 151(1):58-64. PubMed ID: 10761564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interferon and steroid treatment in patients with chronic hepatitis C and antinuclear or anti-liver-kidney microsomal antibodies.
    Provenzano G; Almasio P; Fabiano C; Magrin S; Pinzello G; Vaccaro A; Craxì A
    Ital J Gastroenterol; 1996 Sep; 28(7):377-80. PubMed ID: 8937938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response.
    Espinosa M; Rodriguez M; Martin-Malo A; Alvarez de Lara MA; Gonzalez R; Lopez-Rubio F; de la Mata M; Aljama P
    Clin Nephrol; 2001 Mar; 55(3):220-6. PubMed ID: 11316242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Heterogeneity of antimicrosomal autoantibodies in chronic hepatitis C virus infection and delta hepatitis].
    Durazzo M; Costa C; Schmidt E; Loges S; Scaglione L; Touscoz AG; Smedile A; Manns MP; Rizzetto M; Pagano G
    Ann Ital Med Int; 1995; 10(2):93-7. PubMed ID: 7542466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon therapy in HCV-positive mixed cryoglobulinaemia: viral and host factors contributing to efficacy of the therapy.
    Mazzaro C; Carniello GS; Colle R; Doretto P; Mazzi G; Crovatto M; Santini GF; Tulissi P; Gregoretti M; Mazzoran L; Russo A; Silvestri F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):343-50. PubMed ID: 9476189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies of the effectiveness of interferon alpha treatment for chronic hepatitis C in children.
    Czerwionka-Szaflarska M; Chrobot A; Szaflarska-Szczepanik A
    Med Sci Monit; 2000; 6(5):964-70. PubMed ID: 11208439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autoantibodies in children with chronic hepatitis B infection and the influence of interferon alpha.
    Kansu A; Kuloğlu Z; Demirçeken F; Girgin N
    Turk J Gastroenterol; 2004 Dec; 15(4):213-8. PubMed ID: 16249973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C.
    Karino Y; Toyota J; Sugawara M; Higashino K; Sato T; Ohmura T; Suga T; Okuuchi Y; Matsushima T
    Am J Gastroenterol; 1997 Jan; 92(1):61-5. PubMed ID: 8995939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation.
    Casanovas-Taltavull T; Baliellas C; Benasco C; Serrano TT; Casanova A; Pérez JL; Guerrero L; González MT; Andres E; Gil-Vernet S; Casais LA
    Am J Gastroenterol; 2001 Apr; 96(4):1170-7. PubMed ID: 11316166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.
    Cassani F; Cataleta M; Valentini P; Muratori P; Giostra F; Francesconi R; Muratori L; Lenzi M; Bianchi G; Zauli D; Bianchi FB
    Hepatology; 1997 Sep; 26(3):561-6. PubMed ID: 9303483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients.
    Kitazawa E; Igarashi T; Kawaguchi N; Matsushima H; Kawashima Y; Hankins RW; Miyakawa H
    J Autoimmun; 2001 Nov; 17(3):243-9. PubMed ID: 11712862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].
    Wu CH; Xu XY; Tian GS; Yu YY
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):390-3. PubMed ID: 16677548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.